Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H11NO4S |
| Molecular Weight | 253.274 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=C2N=CC=CC2=C(C=C1)S(O)(=O)=O
InChI
InChIKey=YAMVZYRZAMBCED-UHFFFAOYSA-N
InChI=1S/C11H11NO4S/c1-2-16-9-5-6-10(17(13,14)15)8-4-3-7-12-11(8)9/h3-7H,2H2,1H3,(H,13,14,15)
| Molecular Formula | C11H11NO4S |
| Molecular Weight | 253.274 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20860695Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22480421 | https://www.ncbi.nlm.nih.gov/pubmed/23075132
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20860695
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/22480421 | https://www.ncbi.nlm.nih.gov/pubmed/23075132
Actinoquinol is sunscreen agent that absorbs Ultraviolet B light. Actinoquinol in combination with hyaluronic acid drops might be helpful for the human eye in the defense against photooxidative and other oxidative processes.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0010224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20860695 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22480421
The sterile buffered solution of 0.2 % actinoquinol with 0.15 % hyaluronic acid, pH 7.2 was dropped on the right eye (one drop every 30 s, five drops in total)
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23075132
The inhibition of EBV-EA activation was assayed using the EBV genome carrying lymphoblastoid Raji cells of human origin, which were cultivated in RPMI 1640 medium. The cells were incubated at 370 C for 48 h in 1 mL of the medium containing butyric acid (4 mM, as co-inducer), TPA (20 ng/mL, 32 pM) and a known amount of Actinoquinol in DMSO. Smears were made from cell suspension. The EBV-EA-expressing cells were stained with high titre EBV-EA-positive serum from nasopharyngeal carcinoma patients and detected by an indirect immunofluorescence technique. In each assay, 500 cells were counted, and the experiments were carried out in triplicate. The average EA induction was compared to that of a positive control experiment with butyric acid (4 mM) and TPA (32 pM).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:43:45 GMT 2025
by
admin
on
Mon Mar 31 18:43:45 GMT 2025
|
| Record UNII |
470VQE23O3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C28394
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Actinoquinol
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
m5
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | Merck Index | ||
|
3664
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
15301-40-3
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
165584
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
C76254
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
SUB05256MIG
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
CHEMBL1356732
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
100000087695
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
23674
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
DTXSID4046521
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
470VQE23O3
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
239-334-9
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
C556636
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY | |||
|
1626
Created by
admin on Mon Mar 31 18:43:45 GMT 2025 , Edited by admin on Mon Mar 31 18:43:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |